Literature DB >> 10023582

[Diagnosis of myocardial vitality using contrast echocardiography--ready for routine clinical use?].

C Firschke1.   

Abstract

The most benefit from the evaluation of myocardial viability in coronary artery disease is expected in patients with reduced left ventricular function. There is increasing evidence that the outcome of this patient group is better after revascularization if viable myocardium was present before as compared to patients without pre-reperfusion myocardial viability. Therefore, diagnostic tools for the detection of viable myocardium are of enormous therapeutic and economic relevance. The contrast echocardiographic demonstration of myocardial microvascular integrity has been demonstrated to be a corollary of myocellular viability in the experimental and clinical setting. In animal models of reperfusion in acute myocardial infarction, it could be demonstrated that myocardial echocontrast defects, however, only accurately estimate the extent of microvascular damage and the amount of viable tissue after reactive hyperemia has abated. In patients, immediately after reperfusion of the infarct-related artery in acute myocardial infarction, myocardial areas of no reflow could be detected using contrast echocardiography. It has been shown that these myocardial segments exhibit significantly reduced recovery of regional contractile function weeks after reperfusion. In contrast, regions with myocardial microvascular integrity as defined by contrast echocardiography recover function to a significantly higher degree. Furthermore, in patients with remote myocardial infarction, myocardial opacification by contrast echocardiography indicates myocardial collateral perfusion with preserved tissue viability and a high probability of functional recovery after reperfusion. In patients with chronic coronary artery disease and reduced left ventricular ejection fraction, functional recovery could be predicted by myocardial contrast echocardiography with a very high sensitivity in several studies. The lower specificity of the technique may be due to the fact that recovery of contractile function after reperfusion may not be expected in all segments at rest (which was used as the gold standard for viability evaluation in these studies) but rather during physical or pharmacological stress. Therefore, post-reperfusion demonstration of contractile reserve might be a more adequate criterion for the assessment of diagnostic accuracy of myocardial contrast echocardiography for pre-reperfusion viability detection. So far, for the evaluation of myocardial viability, myocardial contrast echocardiography has been exclusively performed using intracoronary injection of echo contrast media; based on the evidence from various studies, this technique is ready for routine clinical application; the place of venous myocardial contrast echocardiography for this purpose, which is an extremely promising technique, however, remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10023582     DOI: 10.1007/bf03043755

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  32 in total

1.  Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial.

Authors:  P Marino; L Zanolla; P Zardini
Journal:  J Am Coll Cardiol       Date:  1989-11-01       Impact factor: 24.094

2.  Contractile versus microvascular reserve for the determination of the extent of myocardial salvage after reperfusion. The effect of residual coronary stenosis.

Authors:  J Sklenar; G Camarano; N C Goodman; S Ismail; A R Jayaweera; S Kaul
Journal:  Circulation       Date:  1996-09-15       Impact factor: 29.690

3.  Assessment of regional myocardial blood flow with myocardial contrast two-dimensional echocardiography.

Authors:  S Kaul; P Kelly; J D Oliner; W P Glasheen; M W Keller; D D Watson
Journal:  J Am Coll Cardiol       Date:  1989-02       Impact factor: 24.094

4.  Two-dimensional echocardiography and infarct size: relationship of regional wall motion and thickening to the extent of myocardial infarction in the dog.

Authors:  A N Lieberman; J L Weiss; B I Jugdutt; L C Becker; B H Bulkley; J G Garrison; G M Hutchins; C A Kallman; M L Weisfeldt
Journal:  Circulation       Date:  1981-04       Impact factor: 29.690

5.  Myocardial infarction in the conscious dog: three-dimensional mapping of infarct, collateral flow and region at risk.

Authors:  B I Jugdutt; G M Hutchins; B H Bulkley; L C Becker
Journal:  Circulation       Date:  1979-11       Impact factor: 29.690

6.  Combined use of dobutamine echocardiography and myocardial contrast echocardiography in predicting regional dysfunction recovery after coronary revascularization in patients with recent myocardial infarction.

Authors:  L Agati; P Voci; C Autore; R Luongo; G Testa; M T Mallus; A Di Roma; F Fedele; A Dagianti
Journal:  Eur Heart J       Date:  1997-05       Impact factor: 29.983

7.  Comparison of myocardial contrast echocardiography and low-dose dobutamine stress echocardiography in predicting recovery of left ventricular function after coronary revascularization in chronic ischemic heart disease.

Authors:  C R deFilippi; D L Willett; W N Irani; E J Eichhorn; C E Velasco; P A Grayburn
Journal:  Circulation       Date:  1995-11-15       Impact factor: 29.690

8.  Regional redistribution of myocardial blood flow after coronary occlusion and reperfusion in the conscious dog.

Authors:  F C White; M Sanders; C M Bloor
Journal:  Am J Cardiol       Date:  1978-08       Impact factor: 2.778

9.  Results of coronary artery surgery in patients with poor left ventricular function (CASS).

Authors:  E L Alderman; L D Fisher; P Litwin; G C Kaiser; W O Myers; C Maynard; F Levine; M Schloss
Journal:  Circulation       Date:  1983-10       Impact factor: 29.690

10.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.